Lipid peroxidation and homocysteine levels in Behçet's disease

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 9, 2006, Pages 1115-1118

  Mungan, A Görkem ^a   Can, Murat ^a   Açikgöz, Serefden ^a   Eştürk, Emel ^a   Altinyazar, Cevdet ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Homocysteine; Lipid peroxidation; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HOMOCYSTEINE; LIPID; MALONALDEHYDE;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; BEHCET SYNDROME; FEMALE; HOMOCYSTEINE; HUMANS; LIPID METABOLISM; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 33748555233     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.191     Document Type: Article

References (34)

1. Behçet H. Über residivierende Aphthose, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937;105:1152-7.
2. Ghate JV, Jorizzo JL. Behçet's disease, and complex aphthosis. J Am Acad Dermatol 1999;40:1-18.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999;341:1284-91.
4. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13.
5. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-72.
6. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenbalt M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulf-hydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.
7. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behcet's disease - endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982;49:247-55.
8. Takeno M, Kariyone A, Yamashita N. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA B51 transgenic mice. Arthritis Rheum 1995;38:426-33.
9. Kose K, Yazici C, Ascioglu O. The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behcet's disease. Clin Biochem 2001;34:125-9.
10. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol 2001;37:517-20.
11. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005;50:297-350.
12. Ozdemir R, Barutcu I, Sezgin AT, Acikgoz N, Ermis N, Metin Esen A, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol 2004;94:522-5.
13. Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet's disease. Br J Ophthalmol 2004;88:1256-8.
14. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80.
15. Hunter MI, Nlemadim BC, Davidson DI. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985;10:1645-52.
16. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
17. Erkilic K, Evereklioglu C, Cekmen M, Ozkiriş A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003;12:107-16.
18. Kokcam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behcet's disease. Clin Biochem 2002;35:633-9.
19. Kose K, Yazici C, Cambay N, Ascioglu O, Dogan P. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behcet's disease. Tohoku J Exp Med 2002;197:9-16.
20. Geisel J, Hubner U, Bodis M, Schorr H, Knapp JP, Obeid R, et al. The role of genetic factors in the development of hyperhomocysteinemia. Clin Chem Lab Med 2003;41:1427-34.
21. Draper H, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990;186:421-31.
22. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
23. Sanvanich P, Mackness B, Gaskell SJ, Durrington P, Mackness M. The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem Biophys Res Commun 2003;300:501-6.
24. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffmann A, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase like activities. Circulation 2000;101:2510-7.
25. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-72.
26. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.
27. Ates A, Aydintug O, Olmez U, Duzgun N, Duman M. Serum homocysteine level is higher in Behcet's disease with vascular involvement. Rheumatol Int 2005;25:42-4.
28. Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behcet's disease. Rheumatol Int 2003;23:236-40.
29. Evereklioglu C, Cumurcu T, Türköz Y, Özerol E, Sahin K, Doganay S. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002;86:653-7.
30. Blacher J, Benetos A, Kirzin JM, Malmejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002;90:591-5.
31. Stuart MJ. Platelet malonyldialdehyde formation: an indicator of platelet hyperfunction. Thromb Haemost 1979;42:649-54.
32. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13:2277-83.
33. Jakubowski H. Homocysteine thiolactone and S-nitrosohomocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med 2003;41:1462-6.
34. Janel N, Robert K, Chabert C, Ledru A, Gouedard C, Barouki R, et al. Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia. Thromb Haemost 2004;92:221-2.